Published online Mar 14, 2024. doi: 10.3748/wjg.v30.i10.1346
Peer-review started: November 7, 2023
First decision: December 27, 2023
Revised: January 12, 2024
Accepted: February 18, 2024
Article in press: February 18, 2024
Published online: March 14, 2024
Processing time: 128 Days and 2.7 Hours
Additional evidence is needed regarding the association between repeated high-normal alanine transaminase (ALT) measurements and metabolic dysfunction-associated fatty liver disease (MAFLD), and only a few cross-sectional studies have shown that ALT trajectory is associated with the risk of MAFLD. In light of the public health burden of MAFLD in China, we investigated the association between persistently elevated high-normal ALT levels and new-onset MAFLD using an ambispective cohort from a health examination population.
MAFLD has become a growing public health problem and affects up to one-third of the global population, with a heavy disease burden. MAFLD can occur in the presence of normal ALT levels, and a trajectory within the normal range can increase the risk of MAFLD. However, the link between repeated high-normal ALT measurements and new-onset MAFLD has not been well studied.
We investigated the optimal ALT cut-off points for diagnosing MAFLD and the association between repeated high-normal ALT measurements and the risk of new-onset MAFLD in a health examination population in China.
This study used data from an ambispective cohort of individuals from a health examination population in China. Repeated high-normal ALT measurements were assessed by considering equally and unequally weighted cumulative effects of excess high-normal ALT (ehALT), and participants were categorized into quartile groups. We performed multivariable Cox proportional hazards regression analysis to evaluate the association between cumulative ehALT and the risk of new-onset MAFLD and calculated the hazard ratios (HRs) and 95% confidence intervals.
A total of 83.13% of participants with MAFLD had normal ALT levels. The HRs of new-onset MAFLD in the group of patients with 2 or 3 cumulative episodes of ehALT (Q3 and Q4 for the equally and unequally weighted cumulative effects of ehALT) were greater than those in the group with low-normal ALT levels from 2017 to 2019. Additionally, the dose-response relationship indicated that the equally and unequally weighted cumulative effects of ehALT had positive nonlinear relationships with the risk of new-onset MAFLD.
A cohort study of the Chinese adult population revealed that persistently elevated high-normal ALT levels were associated with a dose-dependent increase in the risk of new-onset MAFLD in all participants. The identification and management of high-normal ALT levels for several years may play a crucial role in preventing MAFLD.
Long-term prospective cohort or randomized controlled trials are needed to confirm the relationship between repeated high-normal ALT measurements and new-onset MAFLD. Future studies should focus on whether a healthy lifestyle can improve ALT levels and prevent MAFLD.